Insider Confidence Grows as Biote Executives Increase Holdings Biote Corp. insiders, including CEO Bret Christensen and board members, recently acquired about 260,000 shares, signaling strong confidence in the company's future. Despite missing Q4 2024 earnings and revenue forecasts due to software rollout challenges, analysts at Jefferies and Truist maintain Buy ratings, citing optimism for long-term growth in hormone therapy markets.123